Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes-A Patient-Level Pooled Analysis

被引：0
|
作者：
Giorgino, Francesco
Guja, Cristian
Davies, Melanie J.
Aydin, Hasan
Lauand, Felipe
Souhami, Elisabeth
Melas-Melt, Lydie
Aroda, Vanita R.
Rosenstock, Julio
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-773-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
773-P
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
    Woo, Vincent C.
    CANADIAN JOURNAL OF DIABETES, 2020, 44 (01) : 61 - 67
  • [22] Solution is not simple; sodium-glucose cotransporter-2 inhibitor use in Conn syndrome
    Soyaltin, Utku
    BLOOD PRESSURE MONITORING, 2024, 29 (04) : 195 - 197
  • [23] Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor
    Zhang, Lydia
    Tamilia, Michael
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (25) : E766 - E768
  • [24] The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
    Tan, Jinmei
    Guo, Aili
    Zhang, Keqin
    Jiang, Yanli
    Liu, Huaning
    BMC MUSCULOSKELETAL DISORDERS, 2024, 25 (01)
  • [25] Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
    Wei, Jie
    Choi, Hyon K.
    Dalbeth, Nicola
    Li, Xiaoxiao
    Li, Changjun
    Zeng, Chao
    Lei, Guanghua
    Zhang, Yuqing
    JAMA NETWORK OPEN, 2023, 6 (08) : E2330885
  • [26] Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-analysis
    Alexander, Jason
    Staab, Erin M.
    Wan, Wen
    Franco, Melissa
    Knitter, Alexandra C.
    Thomas, Celeste C.
    Press, Valerie G.
    Zeytinoglu, Meltem
    Skandari, Reza
    Gunter, Kathryn E.
    Bindon, Brittany
    Jumani, Sanjay
    Bolen, Shari D.
    Maruthur, Nisa M.
    Huang, Elbert
    Philipson, Louis H.
    Laiteerapong, Neda
    DIABETES, 2020, 69
  • [27] Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
    Kramer, Caroline K.
    Zinman, Bernard
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 323 - 334
  • [28] Stroke safety with Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor use: a systematic review and meta-analysis
    Roddick, A. J.
    Zheng, S. L.
    DIABETOLOGIA, 2018, 61 : S308 - S308
  • [29] Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting
    Rosenstock, Julio
    Ali, Amar
    Meier, Juris J.
    Giorgino, Francesco
    Guja, Cristian
    Prazny, Martin
    Lubwama, Robert
    Souhami, Elisabeth
    Blonde, Lawrence
    DIABETES, 2020, 69
  • [30] Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient
    Haddadin, Rakahn
    Aboujamra, Danny
    Iraninezhad, Homayon
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
12345